Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience

SOD1-ALS from Gene Discovery to Targeted Therapeutics: A Comprehensive Review

Joshua Newman, Phillipe Corcia, Angela Genge

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

touchREVIEWS in Neurology. 2025;21(1):Online ahead of journal publication

Multiple Sclerosis

EAN 2016 Celia Oreja Guevara Interview

Published Online: Jun 30th 2016

Celia Oreja-Guevara reviews the most exciting developments in MS therapy over the last year.

This Content is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study

Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]

Related Videos in Multiple Sclerosis

Developed by Touch

Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis

The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) ...

Developed by Touch

Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis

The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) ...

Developed by Touch

Highlights from EAN 2023!

...

Developed by Touch

Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis - Phase 3 results from EVOLVE-MS-1

The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the ...

Developed by Touch

Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate - Analysis from phase 3 EVOLVE-MS-1 study

Dominic Shadbolt: ECTRIMS Patient perspective - Lifestyle interventions as part of a management plan for MS

We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...

Developed by Touch

Dominic Shadbolt: ECTRIMS Patient perspective - Technologies and tools to predict patient outcomes in MS

Developed by Touch

Dominic Shadbolt: ECTRIMS Patient perspective - The importance of early intervention in MS

Developed by Touch

Georgina Arrambide, ECTRIMS 2022: Serum neurofilament light chain (sNfL) Z score cut-offs in multiple sclerosis

Serum neurofilament light chain (sNfL) levels in MS are associated with inflammatory activity and less clearly with disability. In this touchNEUROLOGY interview, we caught up with Dr Georgina Arrambide (Cemcat, Vall d´Hebron University Hospital, Barcelona, Spain) to discuss the ...

Nele Handwerker: Living with MS – living life to the full

Ms Nele Handwerker is living with multiple sclerosis (MS), and is a patient advocate. She joins us for World Brain day and shares the story of her MS diagnosis. Nele discusses strategies and resources that she believes could help improve ...

Developed by Touch

Barbara Willekens, EAN 2022: Predictors of disease progression and outcome in multiple sclerosis - Highlights

Cognitive impairment can predict physical disability progression in multiple sclerosis (MS). It was a pleasure to speak with Dr Barbara Willekens (Antwerp University Hospital, Edegem, Belgium), who talked through some of the presentations given in this EAN 2022 session on predictors ...

Developed by Touch

Melinda Magyari, EAN 2022: Real-world evidence for disease-modifying therapies in multiple sclerosis

Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Journals

Specialities

SOD1-ALS from Gene Discovery to Targeted Therapeutics: A Comprehensive Review

Learning Activities

Journals

Specialities

SOD1-ALS from Gene Discovery to Targeted Therapeutics: A Comprehensive Review

EAN 2016 Celia Oreja Guevara Interview

This Content is for
Members Only

Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study

Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis

Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis

Highlights from EAN 2023!

Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis - Phase 3 results from EVOLVE-MS-1

Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate - Analysis from phase 3 EVOLVE-MS-1 study

Dominic Shadbolt: ECTRIMS Patient perspective - Lifestyle interventions as part of a management plan for MS

Dominic Shadbolt: ECTRIMS Patient perspective - Technologies and tools to predict patient outcomes in MS

Dominic Shadbolt: ECTRIMS Patient perspective - The importance of early intervention in MS

Georgina Arrambide, ECTRIMS 2022: Serum neurofilament light chain (sNfL) Z score cut-offs in multiple sclerosis

Nele Handwerker: Living with MS – living life to the full

Barbara Willekens, EAN 2022: Predictors of disease progression and outcome in multiple sclerosis - Highlights

Melinda Magyari, EAN 2022: Real-world evidence for disease-modifying therapies in multiple sclerosis

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Journals

Specialities

Trending Topic

Connect With Us:

EAN 2016 Celia Oreja Guevara Interview

This Content is forMembers Only

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Content is for
Members Only

This Functionality is for
Members Only